What question did this study set out to answer?

To determine the immunogenicity and safety of co-administering RSVPreF3 and PCV20 vaccines in adults aged 60 and older.

April 19, 2026Open Access

Immunogenicity and safety of co-administration of adjuvanted respiratory syncytial virus prefusion F protein vaccine with 20-valent pneumococcal conjugate vaccine in adults aged ≥60 years: a randomized, non-inferiority trial

ILIsabel Leroux‐RoelsUniversity College Ghent MLMuriel LinsAmerican University of Integrative Sciences RSRonald SurowitzJupiter Medical Center

Key Points

To determine the immunogenicity and safety of co-administering RSVPreF3 and PCV20 vaccines in adults aged 60 and older.
Conducted a randomized, non-inferiority trial
Participants received either the co-administered vaccines or the vaccines sequentially
Assessed immunogenicity and safety outcomes
Co-administration exhibited non-inferior immunogenicity compared to sequential administration
Both vaccines had an acceptable safety profile
Support for co-administration enhances vaccine uptake

Abstract

Co-administration of adjuvanted RSVPreF3 vaccine and PCV20 vaccine in older adults is immunologically non-inferior to their sequential administration, with an acceptable safety profile. These findings support co-administration as a strategy to enhance vaccine uptake.

Ask AI

Helpful

Bookmark

View Full Paper